7.16
2.98%
-0.22
Titan Pharmaceuticals, Inc. (de) stock is currently priced at $7.16, with a 24-hour trading volume of 10,225.
It has seen a -2.98% decreased in the last 24 hours and a -6.84% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.58 pivot point. If it approaches the $6.87 support level, significant changes may occur.
Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Financials Data
Titan Pharmaceuticals, Inc. (de) (TTNP) Revenue 2022
TTNP reported a revenue (TTM) of $61.00 thousand for the quarter ending December 31, 2022, a -94.79% decline year-over-year.
Titan Pharmaceuticals, Inc. (de) (TTNP) Net Income 2023
TTNP net income (TTM) was -$6.17 million for the quarter ending September 30, 2023, a +39.44% increase year-over-year.
Titan Pharmaceuticals, Inc. (de) (TTNP) Cash Flow 2023
TTNP recorded a free cash flow (TTM) of -$6.42 million for the quarter ending September 30, 2023, a +16.40% increase year-over-year.
Titan Pharmaceuticals, Inc. (de) (TTNP) Earnings per Share 2023
TTNP earnings per share (TTM) was -$8.20 for the quarter ending September 30, 2023, a +52.33% growth year-over-year.
Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Latest News
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
GlobeNewswire Inc.
Gold Moves Lower; Microbot Medical Shares Slide
Benzinga
Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet
Benzinga
Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Benzinga
Kadant, Titan Pharmaceuticals And 3 Stocks To Watch Heading Into Friday
Benzinga
About Titan Pharmaceuticals, Inc. (de)
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Cap:
|
Volume (24h):